Sudarshan Sukhani of s2analytics.com told CNBC-TV18, "Biocon has been a favourite. I would think that any minor correction in Biocon justifies buying. It is an outperformer and has much higher targets."He further added, "The second easier buy is Dr Reddy's Laboratories. It is building a very large and impressive base. It is telling us that the lows have probably been put in place and that is an investment buy."
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
